/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Clearmind Medicine Inc share price today is $0.85, up -11.58%. The stock opened at $0.939 against the previous close of $0.9372, with an intraday high of $0.95 and low of $0.7774.

style

pb-0

Clearmind Medicine Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$0.85 -0.1158(-11.58%) CMND at 13 Mar 2026 12:29 PM Biotechnology

Lowest Today 0.7774

Highest Today 0.95

Today’s Open 0.939

Prev. Close 0.9372

52 Week High 52.40

52 Week Low 0.78

Day’s Range: Low 0.7774 High 0.95

52-Week Range: Low 0.78 High 52.40

Clearmind Medicine Inc Institutional Holdings

Clearmind Medicine Inc Market Status

Clearmind Medicine Inc Fundamentals

Market Cap 1.68 M

PB Ratio 1.4104

PE Ratio 0.0

Enterprise Value -2.12 M

Total Assets 8.53 M

Volume 151879

Clearmind Medicine Inc Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:-69193 -0.1M, FY24:-26703 -0.0M, FY23:-77566 -0.1M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-5405754 -5.4M, FY24:-5254678 -5.3M, FY23:-11627302 -11.6M, FY22:-9410806 -9.4M, FY21:-4122652 -4.1M

Quarterly Revenue Q4/2025:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M

Quarterly Profit Q4/2025:-17993 -0.0M, Q3/2025:-17254 -0.0M, Q2/2025:-16537 -0.0M, Q1/2025:-17742 -0.0M, Q4/2024:-11512 -0.0M

Quarterly Net worth Q4/2025:-964044 -1.0M, Q3/2025:-1809906 -1.8M, Q2/2025:-1083074 -1.1M, Q1/2025:-1579355 -1.6M, Q4/2024:-884744 -0.9M

About Clearmind Medicine Inc & investment objective

Company Information Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post-traumatic stress disorder and other health conditions; and Polyrizon Ltd. to develop novel intranasal MEAI formulation. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*